Novogen to change name, consolidate stocks
Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet
Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback
Infographic: The Big Picture 2023 Sustainability Outlook
The Big Picture for 2023: Assessing Investment Trends and the Impact of Investor Activism
Novogen Ltd is seeking shareholder approval to change its name to Kazia Therapeutics Ltd. and to consolidate its shares.
Novogen intends to implement a 1-for-10 share consolidation to have a more appropriate capital structure as well as reduce administrative costs resulting from a large number of issued shares.
The share consolidation is expected to be effective Dec. 31.
